ADA 2019 Archives - Page 2 of 3 - Endocrinology Advisor

ADA 2019

The ELIXA study found that lixisenatide had a neutral effect on cardiac events.

Empagliflozin Has Cardioprotective Effect in Type 2 Diabetes and CVD

SAN FRANCISCO — Empagliflozin has a consistent cardioprotective effect in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), regardless of the number of CV risk factors that are controlled, according to research presented at the 79th Scientific Sessions of the American Diabetes Association, held June 7 to 11, 2019, in San Francisco. Researchers…

Next post in ADA 79th Scientific Sessions 2019